Introduction
============

Evidence-based optimal medical therapy (OMT) after acute myocardial infarction (AMI) consists of antiplatelet therapy, angiotensin-converting enzyme (ACE) inhibitors/angiotensin II receptor blockers (ARBs), beta-blockers, and statins ([@B1], [@B2]). Since non-adherence to OMT after AMI has been shown to be associated with poor clinical outcomes ([@B3], [@B4]), the importance of OMT is emphasized in contemporary clinical guidelines ([@B5], [@B6]). Nevertheless, the prescription rate of OMT is not sufficiently high in real-word clinical settings. The Tokyo CCU network cohort including 4,329 AMI patients reported that approximately 60% and 40% of AMI patients received ACE inhibitors/ARBs and beta-blockers, respectively ([@B7]). However, why OMT is not prescribed has not been fully discussed.

The present study explored the clinical characteristics of AMI patients who did not receive OMT at the time of hospital discharge.

Materials and Methods
=====================

Study patients
--------------

The present study was a retrospective and single-center study. From our medical records, we included AMI patients who were treated at our institution between January 2015 and December 2016. The diagnosis of AMI required the following criteria: symptoms consistent with AMI, elevated cardiac enzymes including Troponin I and/or creatinine kinase (at least a two-fold increase from the normal upper limit), and ST-segment elevation or depression in electrocardiograms compatible with AMI ([@B8], [@B9]). Furthermore, diagnostic ST-segment elevation was defined as new ST elevation at the J point in at least 2 contiguous leads of 2 mm (0.2 mV); all others were defined as not having ST-segment elevation ([@B10], [@B11]). The exclusion criteria were no coronary angiography, in-hospital death, and second or beyond AMI during the study period. OMT was defined as the combination of antiplatelet therapy (at least single), ACE inhibitors/ARBs, beta-blockers, and statins at the time of hospital discharge. Non-OMT was defined as the lack of either antiplatelet therapy, ACE inhibitors/ARBs, beta-blockers, or statins at the time of hospital discharge. We divided the study patients into OMT and non-OMT groups.

This study was approved by the institutional review board and written informed consent was waived because of the retrospective study design. This study was conducted in accordance with the principles of the Declaration of Helsinki.

Definition
----------

Hypertension was defined as systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or medical treatment for hypertension ([@B9]). Dyslipidemia was defined as a total cholesterol level ≥220 mg/dL or a low-density lipoprotein cholesterol level ≥140 mg/dL or medical treatment for dyslipidemia ([@B9]). Diabetes mellitus was defined as a hemoglobin A1c level ≥6.5% (as NGSP value) or medical treatment for diabetes mellitus ([@B12]). We also calculated the estimated glomerular filtration rate (eGFR) from the serum creatinine levels, age, weight, and gender using the following formula: eGFR=194×Cr^−1.094^×age^−0.287^ (male), eGFR=194×Cr^−1.094^×age^−0.287^×0.739 (female) ([@B13]). An impaired renal function was defined as an eGFR \<60 mL/min/1.73 m^2^ ([@B12]). Shock was defined as systolic blood pressure ≤90 mmHg, need for vasopressors to maintain blood pressure, need for percutaneous mechanical support, or attempted cardiopulmonary resuscitation.

Statistical analyses
--------------------

Data are shown as the mean±standard deviation or percentage. Categorical variables are presented as numbers (percentages) and compared using Pearson\'s χ^2^ test. The Kolmogorov-Smirnov test was performed to determine if the continuous variables were normally distributed. Normally distributed continuous variables were compared between the groups using the unpaired Student\'s *t*-test. Otherwise, continuous variables were compared using the Mann-Whitney U test. Multivariate logistic regression analyses were performed to identify the determinants of non-OMT. In this model, the non-OMT group was used as the dependent variable. The multivariate logistic regression model included covariates found to have significant differences between the OMT and non-OMT groups (defined as p\<0.05). The odds ratios (ORs) and 95% confidence intervals (CIs) were also calculated. A p value \<0.05 was considered statistically significant. We analyzed all data using the SPSS software program, ver. 24, for Windows (SPSS, Chicago, USA).

Results
=======

During the study period, a total of 504 AMI patients were treated at our institution. Of those, 457 AMI patients were included as the final study population and divided into the OMT group (n=359) and non-OMT group (n=98) ([Figure](#g001){ref-type="fig"}). [Table 1](#t001){ref-type="table"} shows the comparison of the background characteristics between the two groups. The mean age was significantly older in the non-OMT group (74±12 years old) than in the OMT group (68±12 years old) (p\<0.001). The eGFR was significantly lower in the non-OMT group (52.3±31.7 mL/min/1.73 m^2^) than in the OMT group (65.9±26.5 mL/min/1.73 m^2^) (p\<0.001). The heart rate on admission was significantly lower in the non-OMT group (72±24 bpm) than in the OMT group (80±23 bpm) (p=0.001). The prevalence of ST-elevation myocardial infarction (STEMI) was significantly lower in the non-OMT group (40.8%) than in the OMT group (65.5%) (p\<0.001). The prevalence of AMI caused by vasospastic angina (VSA) was significantly greater in the non-OMT group (12.2%) than in the OMT group (0.6%) (p\<0.001). Hemoglobin levels on admission was significantly lower in the non-OMT group (12.4±2.2 g/dL) than in the OMT group (13.5±1.9 g/dL) (p\<0.001). The prevalence of a history of malignancy was significantly greater in the non-OMT group (21.4%) than in the OMT group (13.4%) (p=0.048). Blood transfusion during admission was more frequently performed in the non-OMT group (34.7%) than in the OMT group (8.9%) (p\<0.001).

![Patient flowchart.](1349-7235-59-1489-g001){#g001}

###### 

Comparison of Patient Characteristics between the OMT and Non-OMT Groups.

  -----------------------------------------------------------------------------------------------------------------------
  Patient characteristics                                            All\         OMT group\   Non-OMT group\   p value
                                                                     (n=457)      (n=359)      (n=98)           
  ------------------------------------------------------------------ ------------ ------------ ---------------- ---------
  Age, years                                                         70±12        68±12        74±12            \<0.001

  Male sex, n (%)                                                    343 (75.1)   269 (74.9)   74 (75.5)        0.906

  Hypertension, n (%)                                                385 (84.2)   307 (85.5)   78 (79.6)        0.154

  Hyperlipidemia, n (%)                                              318 (69.6)   254 (70.8)   64 (65.3)        0.299

  Diabetes mellitus, n (%)                                           203 (44.4)   161 (44.8)   42 (42.9)        0.725

  Chronic obstructive pulmonary disease, n (%)                       14 (3.1)     11 (3.1)     3 (3.1)          1.000

  Asthma, n (%)                                                      12 (2.6)     5 (1.4)      7 (7.1)          0.005

  Chronic kidney disease, n (%)                                      197 (43.1)   139 (38.7)   58 (59.2)        \<0.001

  Serum creatinine, mg/dL                                            1.6±4.4      1.5±4.8      2.1±2.6          \<0.001

  eGFR, mL/min/1.73 m^2^                                             62.9±28.2    65.9±26.5    52.3±31.7        \<0.001

  Hemodialysis, n (%)                                                30 (6.6)     17 (4.7)     13 (13.3)        0.003

  Hemoglobin levels on admission, g/dL                               13.3±2.0     13.5±1.9     12.4±2.2         \<0.001

  Potassium levels (mEq/L)                                           4.2±0.6      4.2±0.5      4.3±0.6          0.095

  Atrial fibrillation, n (%)                                         67 (14.7)    47 (13.1)    20 (20.4)        0.070

  Current smoking, n (%)                                             144 (31.5)   120 (33.4)   24 (24.5)        0.091

  History of malignancy, n (%)                                       69 (15.1)    48 (13.4)    21 (21.4)        0.048

  Previous PCI, n (%)                                                90 (19.7)    64 (17.8)    26 (26.5)        0.055

  Previous CABG, n (%)                                               17 (3.7)     10 (2.8)     7 (7.1)          0.065

  Previous myocardial infarction, n (%)                              75 (16.4)    55 (15.3)    20 (20.4)        0.228

  STEMI, n (%)                                                       275 (60.2)   235 (65.5)   40 (40.8)        \<0.001

  NSTEMI, n (%)                                                      182 (39.8)   124 (34.5)   58 (59.2)        \<0.001

  AMI caused by vasospastic angina, n (%)                            14 (3.1)     2 (0.6)      12 (12.2)        \<0.001

  Killip 1 or 2, n (%)                                               369 (80.7)   294 (81.9)   75 (76.5)        0.233

  Systolic blood pressure on admission, mmHg                         138±33       140±33       130±35           0.021

  Diastolic blood pressure on admission, mmHg                        79±21        80±21        72±22            0.001

  Heart rate on admission, bpm                                       79±23        80±23        72±24            0.001

  Shock status, n (%)                                                62 (13.6)    45 (12.5)    17 (17.3)        0.218

  Cardio-pulmonary arrest, n (%)                                     21 (4.6)     15 (4.2)     6 (6.1)          0.417

  Catecholamine use before coronary angiography, n (%)               44 (9.6)     30 (8.4)     14 (14.3)        0.078

  Use of intra-aortic balloon pumping, n (%)                         61 (13.3)    44 (12.3)    17 (17.3)        0.189

  Use of veno-arterial extra-corporeal membrane oxygenation, n (%)   11 (2.4)     6 (1.7)      5 (5.1)          0.063

  Blood transfusion during hospitalization, n (%)                    66 (14.4)    32 (8.9)     34 (34.7)        \<0.001
  -----------------------------------------------------------------------------------------------------------------------

Categorical variables were compared using the Pearson χ^2^ test. Normally distributed continuous variables were compared using the unpaired Student's t test. Non-normally distributed continuous variables were compared using the Mann-Whitney U test.

OMT: optimal medical therapy, eGFR: estimate glomerular filtration rate, PCI: percutaneous coronary intervention, CABG: coronary artery bypass graft surgery, STEMI: ST-segment elevation myocardial infarction, NSTEMI: non-ST-segment elevation myocardial infarction, AMI: acute myocardial infarction

[Table 2](#t002){ref-type="table"} shows the comparison of the lesion and therapeutic characteristics between the OMT and non-OMT groups. Percutaneous coronary intervention (PCI) was more frequently selected in the OMT group (95.5%) than in the non-OMT group (71.4%). Peak creatinine kinase (CK) and creatinine kinase-myocardial band (CK-MB) levels were significantly greater in the OMT group than in the non-OMT group. In the overall study population, the prescription rates of antiplatelet therapy, ACE inhibitors/ARBs, beta-blockers, and statins were 98.7%, 87.5%, 90.4%, and 96.7%, respectively. In addition, we compared the clinical characteristics between patients who did and did not receive antiplatelet therapy ([Supplementary material 1](#s001){ref-type="supplementary-material"}), between patients who did and did not receive ACE inhibitors/ARBs ([Supplementary material 2](#s002){ref-type="supplementary-material"}), between patients who did and did not receive beta-blockers ([Supplementary material 3](#s003){ref-type="supplementary-material"}), and between patients who did and did not receive statins ([Supplementary material 4](#s004){ref-type="supplementary-material"}).

###### 

Comparison of Lesion and Therapeutic Characteristics between the OMT and Non-OMT Groups.

  ------------------------------------------------------------------------------------------------------------
                                                        All (n=457)   OMT group\    Non-OMT group\   p value
                                                                      (n=359)       (n=98)           
  ----------------------------------------------------- ------------- ------------- ---------------- ---------
  Infarct related artery                                                                             0.876

  Left main-left anterior descending artery, n (%)      237 (51.9)    188 (52.4)    49 (50.0)        

  Left circumflex artery, n (%)                         58 (12.7)     47 (13.1)     11 (11.2)        

  Right coronary artery, n (%)                          158 (34.6)    121 (33.7)    37 (37.8)        

  Bypass graft vessel, n (%)                            4 (0.9)       3 (0.8)       1 (1.0)          

  Number of narrowed coronary arteries                                                               0.445

  1                                                     246 (53.9)    190 (53.1)    56 (57.1)        

  2                                                     135 (29.6)    111 (31.0)    24 (24.5)        

  3                                                     75 (16.4)     57 (15.9)     18 (18.4)        

  Type of revascularization                                                                          \<0.001

  PCI only, n (%)                                       411 (89.9)    343 (95.5)    68 (69.4)        

  CABG, n (%)                                           17 (3.7)      6 (1.7)       11 (11.2)        

  PCI and CABG, n (%)                                   2 (0.4)       0 (0.0)       2 (2.0)          

  Medication and others, n (%)                          27 (5.9)      10 (2.8)      17 (17.3)        

  Any PCI, n (%)                                        413 (90.4)    343 (95.5)    70 (71.4)        \<0.001

  Type of PCI (n=413)                                                                                0.053

  Drug-eluting stent use, n (%)                         369 (89.3)    312 (91.0)    57 (81.4)        

  Bare metal stent use, n (%)                           18 (4.4)      12 (3.5)      6 (8.6)          

  Others, n (%)                                         26 (6.3)      19 (5.5)      7 (10.0)         

  Final TIMI-3 flow, n (%)                              424 (92.8)    333 (92.8)    91 (92.9)        0.973

  Outcomes                                                                                           

  Peak creatinine kinase level, mU/mL                   1,468±2,336   1,622±2,536   902±1,226        0.001

  Peak creatinine kinase-myocardial band level, mU/mL   128±175       144±186       67±110           \<0.001

  Left ventricular ejection fraction, (%)               55.0±13.8     55.5±13.4     53.0±13.2        0.077

  Length of hospital stay, days                         11±11         10±8          16±16            0.002

  Medication at discharge                                                                            

  Antiplatelet therapy (at least single)                451 (98.7)    359 (100)     92 (93.9)        \-

  ACE inhibitors/ARBs                                   400 (87.5)    359 (100)     41 (41.8)        \-

  Beta-blockers                                         413 (90.4)    359 (100)     54 (55.1)        \-

  Statins                                               442 (96.7)    359 (100)     83 (84.7)        \-
  ------------------------------------------------------------------------------------------------------------

Categorical variables were compared using the Pearson χ^2^ test. Normally distributed continuous variables were compared using the unpaired Student's t test. Non-normally distributed continuous variables were compared using the Mann-Whitney U test. OMT: optimal medical therapy, TIMI: thrombolysis in myocardial infarction, ACE: angiotensin converting enzyme, ARBs: angiotensin II receptor blockers

[Table 3](#t003){ref-type="table"} shows the results of a multivariate logistic regression analysis to identify the determinants of non-OMT group. Age (per 1-year increase: OR 1.033, 95% CI 1.007-1.059, p=0.014), hemodialysis (vs. no hemodialysis: OR 2.707, 95% CI 1.082-6.774, p=0.033), eGFR\<30 mL/min/1.73 m^2^ without hemodialysis (OR 4.585, 95% CI 1.975-10.644, p\<0.001), AMI caused by VSA (vs. no VSA: OR 13.198, 95% CI 1.809-96.260, p=0.011), and asthma (vs. no asthma: OR 7.241, 95% CI 1.716-30.559, p=0.007) were significantly associated with non-OMT, whereas heart rate on admission (per 1-bpm increase: 0.987, 95% CI 0.975-0.999, p=0.033), any PCI (vs. no PCI: OR 0.156, 95% CI 0.066-0.373, p\<0.001), and STEMI (vs. NSTEMI: OR 0.384, 95% CI 0.218-0.675, p=0.001) were inversely associated with non-OMT.

###### 

Multivariate Logistic Regression Analysis to Identify the Determinants of Non-OMT Group.

  Variables                                                      Multivariate logistic regression analysis                  
  -------------------------------------------------------------- ------------------------------------------- -------------- ---------
  Age (per 1 year increase)                                      1.033                                       1.007-1.059    0.014
  Systolic blood pressure on admission (per 1 mmHg increase)     0.994                                       0.986-1.003    0.202
  Heart rate on admission (per 1 bpm increase)                   0.987                                       0.975-0.999    0.033
  Hemoglobin levels on admission (per 1 g/dL increase)           0.885                                       0.756-1.036    0.129
  Hemodialysis (vs. non-hemodialysis)                            2.707                                       1.082-6.774    0.033
  eGFR\<30 mL/min/1.73 m^2^ without hemodialysis                 4.585                                       1.975-10.644   \<0.001
  Any PCI (vs. no PCI)                                           0.156                                       0.066-0.373    \<0.001
  AMI caused by Vasospastic angina (vs. no vasospastic angina)   13.198                                      1.809-96.260   0.011
  STEMI (vs. NSTEMI)                                             0.384                                       0.218-0.675    0.001
  Asthma (vs. no asthma)                                         7.241                                       1.716-30.559   0.007
  History of malignancy (vs. no malignancy)                      1.684                                       0.843-3.362    0.140

OMT: optimal medical therapy, PCI: percutaneous coronary intervention, eGFR: estimate glomerular filtration rate, AMI: acute myocardial infarction, STEMI: ST-segment elevation myocardial infarction, NSTEMI: non-ST-segment elevation myocardial infarction

Discussion
==========

A total of 457 AMI patients were included in the present study and divided into 359 patients (78.6%) who had sufficient OMT and 98 (22.4%) who did not have sufficient OMT at the time of hospital discharge. While the prescription rate of each OMT medication was reasonably high (87.5-98.7%), more than 20% of study patients lacked at least 1 OMT medication. Aging, AMI caused by VSA, asthma, and an impaired renal function were significantly associated with non-OMT, whereas heart rate, any PCI, and STEMI were inversely associated with non-OMT. It may be important to recognize the above factors as risk factors for insufficient OMT.

In the present study, aging was associated with non-OMT. Since we prescribe OMT for better clinical outcomes in AMI patients, we might hesitate to prescribe OMT for the very elderly. Yan et al. also reported that advanced age was a negative independent predictor of OMT ([@B14]). The association between AMI caused by VSA and non-OMT may be explained by the association between VSA and beta-blockers. Although no studies have proven a cause-and-effect relationship between beta-blockers and VSA, several case reports suggest that beta-blockers may provoke coronary spasm ([@B15], [@B16]). The administration of beta-blockers alone for VSA was reported to be class III in clinical guidelines ([@B17]). Therefore, we tended to avoid administering beta-blockers to patients with AMI caused by VSA without coronary artery stenosis, especially when the left ventricular function was preserved. We might also avoid introducing antiplatelet therapy to patients with AMI caused by VSA without coronary artery stenosis. The association between asthma and non-OMT may be explained by the association between asthma and beta-blockers, as beta-blockers are generally contraindicated in patients with asthma.

The association between the heart rate and non-OMT may be explained by the non-administration of beta-blockers. Generally, we did not administer beta-blockers to patients with bradycardia (\<50 bpm). In fact, a recent Japanese multicenter registry reported that the introduction of beta-blockers was associated with poor clinical outcomes in AMI patients whose admission heart rate was \<50 bpm ([@B18]). The association between an impaired renal function and non-OMT may be explained by the non-administration of ACE inhibitors/ARBs. While we understand the importance of administering ACE inhibitors/ARBs to patients with an impaired renal function ([@B19]), we might hesitate to administer ACE inhibitors/ARBs to patients with an impaired renal function, as the use of ACE inhibitors/ARBs during coronary angiography may increase the incidence of contrast-induced acute kidney injury ([@B20]). Furthermore, patients with hemodialysis might have hypotension during hemodialysis.

PCI for revascularization was inversely associated with non-OMT, suggesting that AMI patients who underwent CABG for revascularization might not receive OMT. In fact, CABG during hospitalization is reported to be a risk factor for non-OMT ([@B14]). One possible explanation for this is that AMI patients who underwent CABG were managed by cardiovascular surgeons during hospitalization. Unlike cardiovascular physicians, cardiovascular surgeons might not administer OMT to patients who underwent CABG. Furthermore, STEMI was inversely associated with non-OMT, indicating that NSTEMI was associated with non-OMT. Because NSTEMI patients included those whose troponin I levels were significantly elevated while their CK levels were normal, the left ventricular systolic function was preserved in some NSTEMI patients. While the clinical guidelines strongly recommend administering ACE inhibitors to NSTEMI patients with a left ventricular ejection fraction \<40% ([@B21]), the significance of ACE inhibitors for NSTEMI patients with a normal left ventricular ejection fraction has not been established. Therefore, we might not administer ACE inhibitors/ARBs to NSTEMI patients without a reduced ejection fraction.

The clinical implications of the present study should be noted. As we discussed above, some reasons for non-OMT might be unavoidable, especially for patients with AMI caused by VSA. However, there is likely room for improvement, especially for patients with an advanced age. Since Japan is becoming a super-aged society ([@B22]), secondary prevention for elderly patients should be prioritized, not only for achieving better clinical outcomes but also for reducing medical expenses. However, whether or not OMT is equally effective for the frail elderly, especially for the bedridden elderly, is unclear. A comprehensive discussion regarding OMT for the elderly is warranted, as healthcare resources will be considerably limited in a super-aged society ([@B22]).

Study limitations
-----------------

Several limitations associated with the present study warrant mention. Because this study was a single-center retrospective observational study, there was a risk of selection bias. Our prescription rates of ACE inhibitors/ARBs (87.5%) and beta blockers (90.4%) were considerably higher than the prescription rates of ACE inhibitors/ARBs (60%) and beta blockers (40%) in contemporary Japanese AMI registries ([@B7]), partly because we introduced a novel acute myocardial infarction risk stratification system (nARS) in April 2015 ([@B23], [@B24]). In the nARS, the early introduction of ACE inhibitors/ARBs was strongly encouraged by our daily conference ([@B23]). Therefore, the reasons for non-OMT in our study may be different from those in contemporary Japanese AMI registries. The present study focused on the OMT at the time of hospital discharge. We were unable to conduct monitoring to see whether or not OMT was maintained after hospital discharge. Finally, because we did not routinely check the low-density lipoprotein cholesterol levels following statin administration during hospitalization, the statin dose might not have been titrated at the time of hospital discharge.

Conclusion
==========

Although the prescription rate of each OMT medication was reasonably high (87.5-98.7%), 22.4% of AMI patients lacked at least 1 OMT medication. An advanced age, VSA, bradycardia, asthma, impaired renal function, non-PCI revascularization, and NSTEMI were significantly associated with non-OMT.
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